Abbott Laboratories Q4 Adjusted EPS $1.19, Inline, Sales $10.24B Beat $10.18B Estimate
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories (NYSE:ABT) reported Q4 adjusted EPS of $1.19, meeting analyst estimates, and sales of $10.24B, slightly beating the $10.18B estimate. This represents a 15.53% increase in EPS and a 1.49% increase in sales compared to the same period last year.
January 24, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories reported a solid Q4 with EPS in line with expectations and a slight sales beat, showing growth from the previous year.
Abbott's in-line EPS and better-than-expected sales figures indicate a positive performance, which is likely to be viewed favorably by investors. The year-over-year growth in both earnings and sales suggests a strong financial position, which could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100